OUR DRUG PIPELINE
Synergistic orphan disease product candidates that bridge the treatment gap
ANV221 - A Pre-clinical Research Stage Drug
(Not yet FDA/EU approved - for clinical awareness, research, and investor purposes only)
A novel drug candidate that was superior to approved standard of care drugs in reducing tumor size and suppressing metastasis in mouse models.
“…(Aberrant) glycosylation enables acquisition of all 10 currently accepted hallmarks of cancer” – Institute of Genetic Medicine (2016)*
Several solid tumor cancers have been found to upregulate glycosylation to fuel one or more of their hallmark behaviors. ANV221 is a novel drug candidate that interrupts this cycle leading to:
Disruption of chronic proliferation signaling*
Activation of evolutionary conserved apoptosis (cell suicide) pathways*
Suppressing cell invasiveness, migration and metastasis*
Enhancing tumor vulnerability to other cytotoxic therapies*
With low observed toxicity*
ANV221 was awarded Orphan Drug Designation for the treatment of Pancreatic Cancer by the FDA.
"Tumors were disappeared reduced in two weeks."
- Michio Kurosu, PhD University of Tennessee Health Science Center
*Oncotarget. 2016; 7:35478-35489. https://doi.org/10.18632/oncotarget.8155